LIDDS has announced that the United States Patent and Trademark Office has registered the trademark NanoZolid. LIDDS thereby has exclusive rights to the trademark for products and services in the
Nordic Life Science
Profile
Barbro Ehnbom has successfully promoted women in their careers, not least within life sciences, and she is herself a living example of the changes she has pushed for.
NLS News
LIDDS has announced that the United States Patent and Trademark Office has registered the trademark NanoZolid. LIDDS thereby has exclusive rights to the trademark for products and services in the
Elypta has raised €6.1 million in a late seed funding round closing in December 2019 and led by Industrifonden and Sciety. Norrsken Foundation’s newly raised impact fund also contributed, marking
A new global ranking puts Lundbeck, AstraZeneca and Novo Nordisk in the top 2% of more than 8,400 companies evaluated for their actions against climate change. The companies’ efforts to
AstraZeneca has announced a programme for zero carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon negative by 2030. The strategy was
AstraZeneca will support UNICEF with a $12.5 million grant to support programming which will reach more than five million young people, train 1,000 youth advocates, and positively shape public policy
A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is
AstraZeneca and MSD have announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate
Idogen has announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. Results from completed tests show that the technology platform
Drug and device development
GeNeuro has announced a collaboration for a new clinical trial of temelimab in multiple sclerosis (MS) with clinical researchers of Karolinska Institutet and the Academic Specialist Center (ASC), Stockholm, Sweden.
Medivir has announced that the phase II study of MIV-711 in patients with osteoarthritis has been published in the journal Annals of Internal Medicine. The title of the article is
Moberg Pharma has completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the
Idogen has announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. Results from completed tests show that the technology platform
Sigrid Therapeutics has announced the publication of a study in mice in the journal Nanomedicine demonstrating the enzyme-blocking effects of mesoporous silica particles (MSPs) introduced to the gut and the
Financing
Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner.
Petri Laine is Managing Partner at Innovestor Ventures, a venture capital arm of Innovestor Group. He has been working with high-growth companies for 20 years and prior to joining Innovestor he
Ingrid Teigland Akay is Managing Partner at Hadean Ventures, a life science fund manager that invests in life science companies across Europe, with a particular focus on the Nordic region.
“It was basically a door that opened. In academia it would take ten or more years to have your own lab, but here I was being invited to do just that.”
EUGEN STEINER, HEALTHCAP
The Nobel Prize
Professor Honjo did not set out to find a cure for cancer but he is glad he did not give up and believes cancer immunotherapy will be the Number One
When your passion and lifelong work are the same. Great things can happen. Just ask James Allison.
The 2018 Nobel Prize in Medicine was awarded to James P. Allison and Tasuku Honjo for ther pioneering work in cancer immunotheraphy.
“Immunotherapy can be combined with almost anything; you can combine it with chemotherapy or radiation as long as you do it right. The benefits of immunotherapy are several; the best one is that once T cells see something different about the cancer cell and attack the cancer, they can be re-activated [if the cancer reoccurs.]” – James Allison
Upcoming events
Temperature Control & Logistics is a hands on conference taking place the 27-30 January 2020 in Düsseldorf to discuss everything logistics, supply chain and temperature controlled for the pharmaceutical industry.
The Temperature Control and Logistics forum remains the industries foremost operational and hands on conference to discuss everything logistics, supply chain and temperature controlled for the Pharmaceutical Industry. Our vision for 2020
Nordic Precision Medicine Forum returns to Stockholm alongside a new co-located forum – Nordic AI in Healthcare and Medicine. The Nordic countries continue to grab the headlines as an incubator
The fourteenth annual BIO-Europe Spring conference is the premier springtime partnering conference for the biotechnology industry. For its 2020 edition, BIO-Europe Spring returns to Paris, France on March 23–25, 2020. Theconference annually attracts the
In a new job
Helena Strigård, M.Sc. Molecular Biotechnology and BA Business Economy, has previously worked as an advisor within research and innovation politics at the Confederation of Swedish Enterprise and as an advisor
The Board of Directors of Immunicum has announced that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra, Immunicum’s
BioArctic will be strengthening its management team in 2020 through two strategic recruitments. As of January 1, Tomas Odergren will assume the role of Chief Medical Officer and as of
Careers
Being part of a fast-paced industry where the technology is constantly evolving is part of what makes life science law an enjoyable challenge, said Attorney Hanna Paloheimo, who oversees the life sciences division at Castrén & Snellman Attorneys of Helsinki.
New issue of NLS is out now!
ISSUE 04 2019 // This issue features an exclusive interview with business woman Barbro Ehnbom, within life sciences perhaps best known as the founder of SALSS. This issue also contains a mini-theme on Drug development. We also reveal new Nordic findings from CryoEM data and we have spoken to Ed Boyden, the winner of the Lennart Nilsson Award.
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
Medivir has announced that the phase II study of MIV-711 in patients with osteoarthritis has been published in the journal Annals of Internal Medicine. The title of the article is
Moberg Pharma has completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the
Following the recommendation from an independent Data Monitoring Committee, AstraZeneca has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood of demonstrating a
NeuroVive Pharmaceutical has announced the completed recruitment of healthy volunteers in the second part of the company’s ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic
Immunovia has announced that the Commercial Test Model study was successful, showing a 95% accuracy, and the company is on track for commercialization of the IMMray PanCan-d commercial biomarker signature.
BerGenBio has provided an update from the company’s phase II study of bemcentinib (BGB324), an oral AXL inhibitor, in combination with low-dose cytarabine (LDAC) in elderly AML patients. The bemcentinib-LDAC
The first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer. The
Gedea Biotech has announced that all patients have been recruited for the multi-center study evaluating the clinical performance of an antibiotic-free treatment for vaginal infections. This pilot study marks the
Follicum has announced that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from
The latest research news from the Nordic region
Science Article
A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is
Researchers at Karolinska Institutet and Tampere University have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer. The AI-system has the potential to
Scientists at SciLifeLab have provided medical research with a detailed description of the proteins in human blood. Published in the journal Science, the Blood Atlas resource is the latest database
A new scientific study showing how fish behavior is being changed by pharmaceuticals entering water habitats after being incorrectly disposed highlights the urgent need for research into the impact of
Spinchem shares about 40 million SEK in an international research project funded by the European Union. ”This is good timing for SpinChem since our strategy is to create new environmentally
A novel map of all proteins secreted to human blood is described in a paper by Mathias Uhlen et al. entitled “The Human Secretome”, published in the journal Science Signaling.
Sign up to our newsletter